China's Medical Tourism and Hospital Investment Surge | Generated by AI
Question: Is it true that international patients (including Southeast Asians) are increasingly coming to China’s major cities for cancer treatment and medical care? Has China really opened up to allow foreigners to own hospitals independently? How is this market developing — especially for hospitals investing in international patients from SEA countries, and what do cancer treatments typically cost (e.g., CNY 100K–500K)?
Answer:
Yes, It Is True — China’s Medical Tourism Boom Is Very Real in 2025–2026
1. The International Patient Surge Is Confirmed
The trend you’re seeing on Xiaohongshu (小红书) is backed by hard data. Major Chinese hospitals treated approximately 1.28 million international patients over the past year, a 73.6% increase compared with three years earlier, according to a 2025 annual report on international medical services from China’s National Health Commission. In Shanghai, the number of overseas patients visiting international departments of public hospitals has risen by double digits since 2024, with more than half receiving inpatient care or surgery.
The upward trend has become more apparent since 2024, according to the director of the International Medical Department at Peking Union Medical College Hospital in Beijing, with foreign patients ranging from long-term expatriates to those traveling specifically for medical care.
2. China’s Historic Opening to Wholly Foreign-Owned Hospitals
Your understanding is correct — this is a genuine and landmark policy change. China announced plans to allow wholly foreign-owned hospitals in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen, and throughout Hainan, via a circular from the Ministry of Commerce, the National Health Commission, and the National Medical Products Administration.
On November 29, 2024, the NHC and three other government departments released a comprehensive work plan for wholly foreign-owned hospitals across those nine locations. Importantly, these hospitals may operate as for-profit or non-profit entities, and high-risk procedures such as organ transplants and experimental cancer therapies are prohibited. At least 50% of management and medical staff must be from mainland China.
Real investment is already flowing in. Singapore-based TTG Group signed a cooperation agreement with Guangzhou’s Baiyun District government in November 2024 to invest one billion RMB to establish TTG International Hospital, anticipated to become a landmark wholly foreign-owned facility.
Singapore’s Perennial Holdings is already operating China’s first wholly foreign-owned tertiary general hospital, targeting 30% of its revenue from international patients in its first year, drawing from Russia, the Middle East, and Southeast Asia.
3. What’s Driving SEA Patients to China?
Lower prices for imported original drugs and medical services, along with efficient consultation processes, have prompted patients from the US, Canada, and Southeast Asia to travel to Shenzhen and Shanghai for treatment.
In the field of targeted cancer treatment, there were cases where patients from the UK and Italy came to hospitals in Shenzhen after ineffective first-, second-, and third-line cancer therapies in their own countries.
Shenzhen is particularly noted for Southeast Asian patients due to English/HK-style hospital management, high-speed rail to Hong Kong for drug access, and efficient cross-border processes.
Hospitals catering to international patients offer concierge services including language interpreters, airport transfers, travel assistance, and accommodation. Leading hospitals have staff fluent in Russian, Arabic, French, Japanese, and Korean, and are also sensitive to religious preferences — offering halal meals, prayer areas, and gender-specific staff.
4. Cancer Treatment Cost Breakdown (CNY)
Your CNY 100K–500K range is broadly accurate for a wide range of scenarios:
Standard Oncology (public/international department): Targeted therapy runs CNY 100,000–200,000 per year, and immunotherapy CNY 100,000–300,000 per year. Total costs range from CNY 150,000–300,000 for early-stage cases to CNY 500,000–1,000,000 for advanced multi-treatment cases.
Surgery specifics: Early-stage laparoscopic surgery costs CNY 50,000–80,000, advanced open surgery exceeds CNY 150,000, and robotic-assisted (Da Vinci) surgery runs CNY 80,000–120,000.
Advanced therapies (proton/CAR-T): CAR-T therapy in China ranges from $120,000 to $200,000 USD, compared to over $400,000 in the United States. Proton and heavy ion therapy packages at top centers like the Shanghai Proton and Heavy Ion Center range from $45,000 to $55,000 USD.
Overall competitiveness vs. the West: Average cancer treatment costs in China range from $15,000 to $50,000 USD, compared to $180,000 in the USA and $130,000 in Germany — typically 50–70% lower.
5. Key Hospitals Targeting International/SEA Patients
| City | Top Hospitals for International Patients |
|---|---|
| Beijing | Peking Union Medical College Hospital, Cancer Hospital of CAMS, Beijing GoBroad Boren Hospital |
| Shanghai | Fudan University Shanghai Cancer Center, Shanghai Proton & Heavy Ion Center, Jiahui International (MGH partner) |
| Guangzhou | Sun Yat-sen University Cancer Center, Fuda Cancer Hospital (JCI), St. Stamford Modern Cancer Hospital |
| Shenzhen | Cancer Hospital CAMS Shenzhen, HKU-Shenzhen Hospital, Peking University Shenzhen Hospital |
| Hainan | Boao Lecheng Pilot Zone (access to unapproved drugs & devices) |
6. Emerging Cutting-Edge Advantage: “The China Gap”
China has moved from a “fast follower” to a global leader in precision medicine. International patients can access cutting-edge clinical trials and advanced immunotherapies years before Western approval — what some call the window between a breakthrough discovery in a Chinese lab and its global availability.
Ivonescimab, a bispecific antibody targeting both PD-1 and VEGF, has become a gold standard for first-line lung cancer treatment in China in 2026, with data showing it reduces disease progression risk by over 50% in EGFR-resistant non-small cell lung cancer.
7. Key Caveats & Challenges
- International patients are not covered by China’s public health insurance. Fees at international departments can be 6 to 12 times higher than standard outpatient rates for Chinese nationals.
- International medical services are capped at no more than 10% of any hospital’s total service capacity, to prevent crowding out domestic patients.
- Wholly foreign-owned hospitals face restrictions: psychiatric, infectious disease, and TCM hospitals are excluded; organ transplants and experimental cancer therapies are prohibited; and data servers must remain within China.
- Insurance integration is still limited — many international patients pay out-of-pocket, though some hospitals accept Cigna and Allianz direct billing.
Summary
The market is very real, growing fast, and 2024–2025 marks a genuine inflection point driven by policy reform (wholly foreign-owned hospitals), the 240-hour visa-free transit policy, and viral social media content on Xiaohongshu and YouTube. For SEA patients, Shenzhen and Guangzhou are especially well-positioned due to geographic proximity, cultural familiarity, and cost-to-quality ratios. CNY 100K–500K covers the realistic cost range for most cancer treatment courses at major public international departments, with advanced therapies like CAR-T or heavy ion therapy running higher.
References:
- ichongqing.info — Foreign Tourists Flock to China for Medical Services (2026)
- yicaiglobal.com — China Draws Growing Number of Overseas Patients (2026)
- people.cn — China Emerging as Cost-Effective Healthcare Destination (2026)
- people.cn — How Far is China from Becoming a Popular Medical Tourism Destination (2025)
- woodburnglobal.com — Expanded Access for Wholly Foreign-Owned Hospitals (2025)
- air-corporate.com — Cell Therapy and Wholly Foreign-Owned Hospitals in China
- en.fudahospital.com — How Much Does Cancer Treatment Cost in China?
- tochinacare.com — Cancer Treatment: Beijing, Shanghai, Guangzhou, Shenzhen Comparison (2026)
- chinacarehealthtours.com — Cancer Treatment in China for Foreign Patients: 2026 Guide
- medbridgenz.com — Medical Tourism China: Heavy Ion & Proton Therapy Guide (2026)